Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Multiple Dose Study of MLN0002 in Ulcerative Colitis
jRCT2080221099Phase 1
- Sponsor
- Takeda
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of vedolizumab in autoimmune colitis (2 arms), sponsored by Takeda.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080221099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221099.